Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02098395 · ClinicalTrials.gov registry record · Phase 3
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 835
- Enrollment target
NCT02098395: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT02098395 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 835 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02098395, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 835 participants
- Enrollment target
Study Summary
This trial is conducted in Africa, Europe and North America. The purpose of the trial is to investigate the efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes.
Primary Outcome
Change from baseline in glycosylated haemoglobin (HbA1c), after 26 weeks of treatment. Full analysis set (FAS = 831) included all randomised subjects who had received at least one dose and had any post-randomisation data.
Interventions
- DRUG placebo
- DRUG liraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 835 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-04 |
| Phase | Phase 3 |
What the finished NCT02098395 record still lists
NCT02098395 is an interventional study that assigns participants to a tested intervention. The registered 835 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02098395 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02098395 about?
NCT02098395 is a clinical study titled "The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes". This trial is conducted in Africa, Europe and North America. The purpose of the trial is to investigate the efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes.
What is the current status of trial NCT02098395?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 835 participants. The study started on 2014-05. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02098395?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG).
Who is sponsoring clinical trial NCT02098395?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02098395's enrollment target sits among peer trials
835 397th of 2000 higher than 1,604 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03670524 · 835 participants · NA
Health, Environment and Action in Louisville (HEAL) Green Heart Louisville Project
- NCT02118467 · 836 participants · Phase 4
Vasoactive Drugs in Intensive Care Unit
- NCT02422550 · 837 participants
Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment
- NCT06910553 · 832 participants
IBD Pregnancy Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia